Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
Streamline your rAAV workflows with simplified lysate purification – enabling faster, more reliable analytics for upstream samples.
Whitepapers/App Notes/Posters

Whitepaper: The performance of PROSOLV® EASYtab SP in four medium-dose

14
SHARES

Posted: 5 April 2019 | | No comments yet

In the present study, the performance of PROSOLV® EASYtab SP was tested in four DC formulations with different model APIs. Each of the selected APIs presented a particular challenge in terms of producing tablets with suitable hardness, weight, uniformity, content uniformity and/or reliable dissolution profiles.

PROSOLV® EASYtab SP was shown to perform considerably better than the corresponding physical mixture of its components for all formulations tested.

    To read this whitepaper in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *


    *


    *


    *


    *


    *


    *


    *

    This content is provided to you for free thanks to the kind support of our sponsors: JRS Pharma

    Share via
    Share via